Castle Biosciences (CSTL)

Castle Biosciences on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as services-medical laboratories.

Download CSV

2.0M

Short interest

settlement 2026-09-30

4.8

Days to cover

-2.6 days vs prior

40.2%

Short share of volume

2026-10-09

Fails to deliver

settlement 2026-09-02

Mon 2 Nov

Next earnings

estimated date

-$8.3M

Insider flow, 90 days

0 buys, 91 sells

As of 2026-10-09.

Short interest

FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSON

As of 30 September 2026, short interest in CSTL is 1,999,726 shares, up 22,972 shares over the last month. Over the last 48 readings it ranged from 1,245,958 shares (15 May 2025) to 1,999,726 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 420K shares a day that is 4.8 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/cstl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-09-30	1,999,726	+5.3%	419,633	4.77
2026-09-15	1,899,369	-3.9%	257,937	7.36
2026-08-31	1,976,754	+12.7%	391,437	5.05
2026-08-14	1,753,605	+12.3%	477,095	3.68
2026-07-31	1,561,988	+9.9%	491,979	3.17
2026-07-15	1,421,793	-4.7%	251,097	5.66
2026-06-30	1,491,750	+0.5%	469,005	3.18
2026-06-15	1,485,061	+0.0%	284,222	5.23
2026-05-29	1,484,771	+4.9%	393,031	3.78
2026-05-15	1,415,745	-0.9%	633,871	2.23
2026-04-30	1,429,016	-2.3%	302,361	4.73
2026-04-15	1,463,047	-4.7%	278,210	5.26
2026-03-31	1,534,400	+7.4%	314,771	4.87
2026-03-13	1,429,011	+2.5%	408,340	3.50
2026-02-27	1,394,294	+2.6%	483,116	2.89
2026-02-13	1,359,050	-10.3%	439,178	3.09
2026-01-30	1,514,895	-1.2%	372,144	4.07
2026-01-15	1,532,958	+1.7%	380,608	4.03
2025-12-31	1,507,676	-12.5%	285,598	5.28
2025-12-15	1,722,466	-6.2%	434,833	3.96
2025-11-28	1,835,348	+11.8%	492,305	3.73
2025-11-14	1,641,694	+6.1%	673,049	2.44
2025-10-31	1,547,250	-3.8%	240,965	6.42
2025-10-15	1,608,069	+3.4%	294,656	5.46

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 9 October 2026, the short share of CSTL volume is 40.2%, down 27.3 points over the last five sessions. Over the last 30 readings it ranged from 23.9% (22 September 2026) to 67.8% (1 October 2026). The latest reading is 7.8 points below the 30-session average of 47.9%, on 71K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-10-09	29K	71K	40.2%	0
2026-10-08	50K	97K	51.4%	0
2026-10-07	65K	126K	51.6%	250
2026-10-06	124K	218K	56.8%	0
2026-10-05	72K	132K	54.3%	0
2026-10-02	35K	52K	67.5%	0
2026-10-01	100K	147K	67.8%	0
2026-09-30	101K	178K	56.8%	0
2026-09-29	32K	89K	35.9%	0
2026-09-28	24K	93K	26.4%	0
2026-09-25	54K	139K	39.1%	0
2026-09-24	66K	138K	47.8%	0
2026-09-23	51K	134K	37.9%	0
2026-09-22	33K	139K	23.9%	0
2026-09-21	39K	121K	31.9%	0
2026-09-18	53K	81K	66.1%	600
2026-09-17	76K	123K	61.9%	5,100
2026-09-16	108K	216K	50.2%	1,629
2026-09-15	79K	177K	44.6%	5
2026-09-14	22K	46K	47.6%	0
2026-09-11	23K	68K	33.9%	0
2026-09-10	37K	100K	37.4%	0
2026-09-09	28K	62K	44.8%	0
2026-09-08	52K	76K	67.8%	0
2026-09-04	32K	68K	47.1%	0
2026-09-03	38K	79K	47.9%	0
2026-09-02	32K	66K	48.7%	0
2026-09-01	83K	135K	61.0%	0
2026-08-31	42K	80K	52.2%	0
2026-08-28	35K	94K	37.4%	0

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 2 September 2026, the fails-to-deliver balance in CSTL is 57 shares, up 29 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (5 November 2025) to 19,689 shares (2 February 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-09-02	57	$33.44	$2K
2026-08-31	28	$33.50	$938
2026-08-20	1,667	$32.32	$54K
2026-08-17	23	$29.62	$681
2026-08-11	559	$32.35	$18K
2026-08-05	101	$31.18	$3K
2026-08-04	46	$30.39	$1K
2026-08-03	10	$28.00	$280
2026-07-22	172	$24.51	$4K
2026-06-29	89	$24.30	$2K
2026-05-29	4	$22.11	$88
2026-05-04	76	$24.81	$2K
2026-04-20	72	$25.05	$2K
2026-04-16	47	$24.62	$1K
2026-03-04	18	$27.57	$496
2026-02-27	1,775	$31.88	$57K
2026-02-05	2,363	$34.96	$83K
2026-02-02	19,689	$39.39	$776K
2026-01-30	13,575	$39.16	$532K
2026-01-07	3	$40.07	$120
2025-12-15	344	$38.63	$13K
2025-12-02	38	$39.12	$1K
2025-11-05	1	$31.63	$32
2025-10-27	68	$24.51	$2K
2025-10-14	470	$22.81	$11K
2025-09-24	1,439	$23.56	$34K
2025-09-15	2,426	$21.42	$52K
2025-08-06	369	$20.35	$8K
2025-08-01	1,081	$15.15	$16K
2025-06-24	46	$18.85	$867

Insider trades

SEC Form 4, newest first, 50 of 100 shown. JSON

Insiders at CSTL reported 91 open-market sells worth $8.3M in the last 90 days and no open-market buys. Latest filing: MAETZOLD DEREK J (Pres. & Chief Exec. Officer) on 2026-10-05.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-10-05	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$35.57	$97K	7K
2026-10-05	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$35.57	$114K	8K
2026-10-05	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	9K	$35.57	$305K	21K
2026-10-05	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Option exercise	8K	$2.39	$20K	30K
2026-10-01	Oelschlager Kristen M	Chief Operating Officer	Sell	1K	$36.38	$49K	13K
2026-10-01	Oelschlager Kristen M	Chief Operating Officer	Sell	3K	$35.75	$100K	15K
2026-10-01	Oelschlager Kristen M	Chief Operating Officer	Option exercise	4K	$3.38	$14K	18K
2026-09-30	Juvenal Tobin W	Chief Commercial Officer	Sell	1K	$34.20	$35K	52K
2026-09-29	Juvenal Tobin W	Chief Commercial Officer	Sell	6K	$35.50	$197K	53K
2026-09-21	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$35.33	$96K	10K
2026-09-21	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$35.33	$113K	11K
2026-09-21	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	9K	$35.33	$303K	21K
2026-09-21	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Option exercise	9K	$2.39	$21K	30K
2026-09-15	Juvenal Tobin W	Chief Commercial Officer	Sell	3K	$35.14	$116K	59K
2026-09-14	Juvenal Tobin W	Chief Commercial Officer	Sell	3K	$32.32	$107K	62K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	71	$32.78	$2K	12K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	83	$32.78	$3K	14K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	223	$32.78	$7K	21K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$32.00	$85K	12K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$32.00	$100K	15K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	8K	$32.00	$268K	22K
2026-09-11	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Option exercise	9K	$2.39	$21K	30K
2026-09-01	Oelschlager Kristen M	Chief Operating Officer	Sell	200	$34.02	$7K	13K
2026-09-01	Oelschlager Kristen M	Chief Operating Officer	Sell	4K	$33.36	$132K	14K
2026-09-01	Oelschlager Kristen M	Chief Operating Officer	Option exercise	4K	$3.38	$14K	18K
2026-08-31	Juvenal Tobin W	Chief Commercial Officer	Sell	2K	$32.81	$57K	65K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	21	$33.88	$711	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	21	$33.88	$711	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	21	$33.88	$711	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	257	$33.14	$9K	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	257	$33.14	$9K	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	257	$33.14	$9K	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	21	$33.88	$711	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	177	$33.88	$6K	15K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	209	$33.88	$7K	18K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	956	$33.88	$32K	21K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	257	$33.14	$9K	11K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	2K	$33.14	$71K	15K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	3K	$33.14	$83K	18K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	11K	$33.14	$380K	22K
2026-08-28	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Option exercise	12K	$2.39	$30K	34K
2026-08-25	Juvenal Tobin W	Chief Commercial Officer	Sell	9K	$35.04	$317K	67K
2026-08-25	Oelschlager Kristen M	Chief Operating Officer	Sell	5K	$34.64	$181K	73K
2026-08-25	Oelschlager Kristen M	Chief Operating Officer	Sell	7K	$34.26	$245K	78K
2026-08-24	Oelschlager Kristen M	Chief Operating Officer	Sell	12K	$33.69	$412K	85K
2026-08-17	Juvenal Tobin W	Chief Commercial Officer	Sell	2K	$29.59	$51K	76K
2026-08-14	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	278	$30.02	$8K	12K
2026-08-14	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	278	$30.02	$8K	12K
2026-08-14	MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sell	278	$30.02	$8K	12K
2026-08-14	Stokes Frank	Chief Financial Officer	Sell	25K	$29.77	$742K	35K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

13 Form 144 notices on file for CSTL worth $4.4M at the prices reported; 2 in the last 90 days worth $889K. Latest: KRISTEN OELSCHLAGER filed on 2026-10-01 to sell 4,153 shares ($148K) from 2026-10-01.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-10-01	KRISTEN OELSCHLAGEROfficer	4K	$148K	0.014%	2026-10-01	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-08-14	FRANKLIN M. STOKESOfficer	25K	$741K	0.082%	2026-08-14	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-06-16	KRISTEN OELSCHLAGEROfficer	30K	$618K	0.099%	2026-06-16	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-05	FRANKLIN STOKESOfficer	6K	$169K	0.020%	2026-03-05	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-05	GORDON B. COLEDirector	7K	$211K	0.025%	2026-03-05	Morgan Stanley Smith Barney LLC Executive Financial Services
2026-03-03	FRANKLIN STOKESOfficer	7K	$196K	0.024%	2026-03-03	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-12-17	Kristen M. OelschlagerOfficer	15K	$581K	0.051%	2025-12-17	J.P. Morgan Securities LLC
2025-12-11	TOBIN JUVENALOfficer	13K	$495K	0.045%	2025-12-11	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-12-11	FRANKLIN M. STOKESOfficer	4K	$168K	0.015%	2025-12-11	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-11-24	TOBIN JUVENALOfficer	1K	$49K	0.004%	2025-11-24	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-11-12	Kristen M. OelschlagerOfficer	19K	$658K	0.065%	2025-11-11	J.P. Morgan Securities LLC
2025-11-12	TOBIN JUVENALOfficer	5K	$187K	0.018%	2025-11-11	Morgan Stanley Smith Barney LLC Executive Financial Services
2025-11-12	FRANKLIN STOKESOfficer	5K	$187K	0.018%	2025-11-11	Morgan Stanley Smith Barney LLC Executive Financial Services

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

2 holders report 5% or more of CSTL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Roderick Wong at 9.3% of the class (2,758,335 shares), filed 2026-05-15 for an event on 2026-03-31.

Filed	Form	Holder	Shares	Of class	Event
2026-05-15	13G/Ano. 1	Roderick Wongparent holding company, individual	2.8M	9.3%	2026-03-31
2026-05-15	13G/Ano. 1	RTW Investments, LPinvestment adviser, partnership	2.8M	9.3%	2026-03-31
2026-05-15	13G/Ano. 1	Portolan Capital Management, LLCinvestment adviser	1.4M	4.5%	2026-03-31
2026-05-15	13G/Ano. 1	George McCabeindividual	1.4M	4.5%	2026-03-31
2026-03-26	13G/Ano. 3	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13
2026-01-21	13G/Ano. 1	Dimensional Fund Advisors LPinvestment adviser	1.1M	3.9%	2025-12-31

13F holders

Tracked managers holding CSTL at their latest 13F. JSON

7 of the 30 tracked managers held CSTL at their latest 13F, $37.7M in total at quarter-end prices. Renaissance Technologies is the largest at $8.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Renaissance Technologies	2026-06-30	371K	$8.9M	0.01%	-162K
Point72 Asset Management	2026-06-30	357K	$8.5M	0.01%	new
Citadel Advisors	2026-06-30	265K	$6.3M	0.00%	+144K
Millennium Management	2026-06-30	205K	$4.9M	0.00%	-148K
AQR Capital Management	2026-06-30	167K	$4.0M	0.00%	+102K
D. E. Shaw & Co.	2026-06-30	113K	$2.7M	0.00%	-99K
Two Sigma Investments	2026-06-30	100K	$2.4M	0.00%	-148K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 FY 2026 (quarter ended 2026-06-30) Castle Biosciences reported revenue of $103.5M, up 20.1% from the same quarter a year earlier, and net loss of $2.1M (-0.07 diluted EPS). In FY 2025 it generated $64.3M of operating cash flow. As of 2026-06-30, cash was $62.1M against $10.1M of debt.

Cash: $62.1M
Debt: $10.1M
Equity: $470.0M
Total assets: $561.2M
Shares outstanding: 30,549,507

Quarterly, last 8 quarters

Quarter	Period end	Revenue	Net income	Margin	Diluted EPS
Q2 FY 2026	2026-06-30	$103.5M	-$2.1M	-2.0%	-0.07
Q1 FY 2026	2026-03-31	$83.7M	-$14.5M	-17.4%	-0.49
Q4 FY 2025derived	2025-12-31	$87.0M	-$2.3M	-2.7%	n/a
Q3 FY 2025	2025-09-30	$83.0M	-$501K	-0.6%	-0.02
Q2 FY 2025	2025-06-30	$86.2M	$4.5M	5.2%	0.15
Q1 FY 2025	2025-03-31	$88.0M	-$25.8M	-29.4%	-0.90
Q4 FY 2024derived	2024-12-31	$86.3M	$9.6M	11.1%	n/a
Q3 FY 2024	2024-09-30	$85.8M	$2.3M	2.6%	0.08

Fiscal years, with buybacks and dividends

Fiscal year	Ends	Revenue	Net income	Operating cash flow	Capex	Buybacks	Dividends
FY 2025	2025-12-31	$344.2M	-$24.2M	$64.3M	$36.0M	n/a	n/a
FY 2024	2024-12-31	$332.1M	$18.2M	$64.9M	$28.3M	n/a	n/a
FY 2023	2023-12-31	$219.8M	-$57.5M	-$5.6M	$13.6M	n/a	n/a
FY 2022	2022-12-31	$137.0M	-$67.1M	-$41.7M	$5.6M	n/a	n/a
FY 2021	2021-12-31	$94.1M	-$31.3M	-$19.0M	$3.5M	n/a	n/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-23 from the cover page.

What this page is

Castle Biosciences in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Castle Biosciences (CSTL), SEC CIK 1447362, listed on Nasdaq, classified by the SEC as services-medical laboratories. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-02.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials: SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-05.JSON and CSV
Company record: EDGAR filing index for CIK 1447362Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as services-medical laboratories

Other company pages

Datasets

Frequently Asked Questions

How much of CSTL is sold short?

1,999,726 shares were held short at the 2026-09-30 settlement, 4.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is CSTL's daily short volume?

On 2026-10-09, 28,527 of the 71,001 CSTL shares reported to FINRA were sold short, 40.2% of the day's reported volume. Short volume is a flow for one day, not a position.

Does CSTL have fails to deliver?

The SEC's latest file shows 57 CSTL shares failed to deliver at settlement 2026-09-02. Fails are reported per settlement date and published twice a month with a lag.

Are CSTL insiders buying or selling?

Insiders at CSTL reported 91 open-market sells worth $8.3M in the last 90 days and no open-market buys. Latest filing: MAETZOLD DEREK J (Pres. & Chief Exec. Officer) on 2026-10-05.

Have CSTL insiders filed to sell?

Who owns 5% or more of CSTL?

What did CSTL report last quarter?

Which tracked 13F managers own CSTL?

7 of the 30 tracked 13F managers held CSTL shares at their latest filing, $37.7M in all. The largest: Renaissance Technologies (371K shares, $8.9M), Steve Cohen's Point72 Asset Management (357K shares, $8.5M), Ken Griffin's Citadel Advisors (265K shares, $6.3M), Izzy Englander's Millennium Management (205K shares, $4.9M), Cliff Asness's AQR Capital Management (167K shares, $4.0M), D. E. Shaw & Co. (113K shares, $2.7M). The table above lists all 7.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.